Pierre Fabre CDMO

Toulouse, France
Pharmaceutical lozenges (hard-boiled sugar, medicated) Tablets Capsules Non-sterile liquids Sterile injectables (fill-finish) APIs (botanical/synthetic) mAb/ADC (clinical batches)
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections ○ Clinical Trials ○ SEC Filings ○ Press ○ EMA GMP ○ MHRA GMP

Quick Facts: Pierre Fabre CDMO

Signal Score
60.0/100
Quality Compliance
Assessment pending
Headquarters
Toulouse, France
Modalities
Pharmaceutical lozenges (hard-boiled sugar, medicated), Tablets, Capsules, Non-sterile liquids, Sterile injectables (fill-finish), APIs (botanical/synthetic), mAb/ADC (clinical batches)
Active Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Pierre Fabre CDMO

Auto-created by AI matchmaker. Data verification pending.

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs — no verified data
Sponsors— no verified data
ModalitiesPharmaceutical lozenges (hard-boiled sugar, medicated), Tablets, Capsules, Non-sterile liquids, Sterile injectables (fill-finish), APIs (botanical/synthetic), mAb/ADC (clinical batches)
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability 60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity 60.0
Broad modality coverage (7 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Broad modality coverage (7 modalities)

Frequently Asked Questions About Pierre Fabre CDMO

What is Pierre Fabre CDMO's CDMO Signal Score?
Pierre Fabre CDMO has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating Pierre Fabre CDMO for a manufacturing program?
Use the free AI matchmaker to compare Pierre Fabre CDMO against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
mAb/ADC (clinical batches) CDMOs →

Similar CDMOs

Biofarma Group
Padua, Italy
Tablets, Capsules, Softgels, Gummies, Probiotics, Vitamins & Minerals, Dietary Supplements, Functional Foods, Nutraceuticals, Medical Devices (Class I/II)
Sirio Pharma
Shantou, China
Softgels, Hard Capsules, Gummies, Tablets, Dietary Supplements, Functional Foods, Nutraceuticals, OTC Products